Allergen-specific immunotherapy (AIT) is the only causal treatment for allergy. However, success rates vary depending on the type of allergy and disease background of the patient. Hence, strategies targeting an increased therapeutic efficacy are urgently needed. The research group of Simon Blank in collaboration with the German Mouse Clinic at the Helmholtz Center Munich (first authors: Dennis Russkamp and Antonio Aguilar-Pimentel) used an recombinantly produced IL-4 and IL-13 antagonist (IL-4 Mutein) to block IL-4 and Il-13 signaling during experimental AIT of murine allergic asthma. Using this strategy, they were able to demonstrate that IL-4 and IL-13 blockade during AIT shows beneficial effects on immunological key parameters such as IgE, IgG and Th2 cytokine secretion as well as significantly decreases the number of potentially disease-triggering Th2-biased Tregs (ST2+FOXP3+GATA3intermediate). Hence, Th2 cytokine-inhibiting strategies might be suitable to support allergen-specific immunotherapy in a therapy success-favoring manner.
IL-4 receptor α blockade prevents sensitization and alters acute and long-lasting effects of allergen-specific immunotherapy of murine allergic asthma
D. Russkamp, A. Aguilar-Pimentel, F. Alessandrini, V. Gailus-Durner, H. Fuchs, C. Ohnmacht, A. Chaker, M. Hrabe de Angelis, M. Ollert, C. B. Schmidt-Weber, S. Blank
Allergy 2019, Epub ahead pf print.